Robust and durable response to first-line treatment of pembrolizumab combined with chemotherapy in two patients with metastatic thymic squamous cell carcinoma: Case report
Thymic carcinoma is a rare and aggressive disease with poor outcome. There is no established treatment regimen for advanced thymic carcinoma. While the efficacy of pembrolizumab was proved to be promising, as a single agent, in patients with refractory/recurrent thymic carcinoma that progressed afte...
Збережено в:
| Автори: | , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Frontiers Media S.A.
2022-08-01
|
| Серія: | Frontiers in Immunology |
| Предмети: | |
| Онлайн доступ: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.941092/full |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|